30 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
27 Feb 24
Zai Lab Announces Full-Year 2023
4:12pm
China submissions:
–Efgartigimod SC in chronic inflammatory demyelinating polyneuropathy (CIDP)
–Adagrasib in second-line+ NSCLC
–Tisotumab vedotin … in chronic plaque psoriasis (CPP)
Enroll patients in the global Phase 1 study for ZL-1310 (DLL3 ADC) in small cell lung cancer (SCLC)
1 Mainland China
8-K
EX-99.1
elvpu 6roe
7 Nov 23
Zai Lab Announces Third Quarter 2023
4:10pm
8-K
EX-99.1
dxhxvcw
7 Aug 23
Zai Lab Announces Second Quarter 2023
4:07pm
8-K
EX-99.1
k4fumyj8lqt
30 Jun 23
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
4:18pm
8-K
EX-99.1
yxwqjur 6el
9 May 23
Zai Lab Announces First Quarter 2023
4:03pm
8-K
EX-99.1
sa374 jwsvho7
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
cjkzhgd24jor 61fu3q1
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
8-K
EX-99.1
lhqz2cr
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
34ifq7e4
1 Mar 22
Results of Operations and Financial Condition
4:17pm
8-K
EX-99.3
5weg2 qegbhv
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm